This interim guidance is aimed at assisting organizers of international meetings attended by individuals from EVD-affected countries and individuals with a travel history to EVD-affected countries within the previous 3 weeks.
The first part is intended for organizers of international meetings, to ...safely plan and conduct these events. The second part is addressed to public health authorities directly involved in supporting such international meetings.
more
This document provides guidelines on the establisment of early surveillance actions to be carried out in countries where no case of Ebola virus disease has been reported.
An alert system should be in place at the following sites: major land border crossing with already affected countries; capital ...cities, including at airports, seaports, and health-care facilities, especially in major hospitals.
The alert system (staff trained in case definitions and able to detect signs and symptoms of disease) should report sick persons coming from country that has reported cases of Ebola virus disease (EVD) and possibly meeting the definition of a case under investigation
more
During the past five decades, the incidence of dengue has increased 30-fold. Some 50–100 million new infections are estimated to occur annually in more than 100 endemic countries, with a documented further spread to previously unaffected areas; every year hundreds of thousands of severe cases ari...se, including 20 000 deaths; 264 disability-adjusted life years per million population per year are lost , at an estimated cost for ambulatory and hospitalized cases of US$ 514–1394, often affecting very poor populations. The true numbers are probably far worse, since severe underreporting and misclassification of dengue cases have been documented.
more
This publication’s primary purpose is to provide a compilation of actions to address malnutrition in all its forms, in a concise and user-friendly format to help in decision-making processes for integration of nutrition interventions in national health policies, strategies, and plans based on coun...try-specific needs and global priorities.
more
The WHO Global Burden of Disease (GBD) study measures the burden of
disease using the disability-adjusted life year metric (DALY). The DALY metric
was developed to assess the burden of disease consistently across diseases,
risk factors and regions. A consistent and comparative description of the ...burden
of diseases and injuries and the risk factors that cause them is important as it
can inform health decision-making and health care planning.
more
If you notice changes in the person’s mood, behaviour, energy levels, habits or
personality, you should consider depression as a possible reason for these changes.
However, you should not attempt to diagnose the person with depression, as only a
trained professional can do this. Do not ignore t...he symptoms you have noticed or
assume that they will just go away
more
The global burden of disease (GBD) study provides information about fatal and non-fatal health outcomes around the world.
The objective of this work is to describe the burden of mental disorders among children aged 5–14 years in each of the six regions of the World Health Organisation. Data come ...from the GBD 2015 study. Outcomes: disability-adjusted life-years (DALYs) are the main indicator of GBD studies and are built from years of life lost (YLLs) and years of life lived with disability (YLDs).
more
Session outline
•Introduction to self-harm/suicide.
•Assessment of self-harm/suicide.
•Management of self-harm/suicide.
•Follow-up.
This manual provides a practical method for determining the pharmacovigilance indices. It is designed to be simple and can be understood by any worker in pharmacovigilance without formal training in monitoring and evaluation. Pharmacovigilance as a medical discipline is crucial in preventing medicin...e-related adverse effects in humans, promoting patient safety, and the rational use of medicines. The indicators proposed in this manual are based on the expected functions of pharmacovigilance centres as described in the WHO Mimimum Requirements for a Functional Pharmacovigilance System (1) (see Annex 1 of the manual).
more